RxDoctor Payments Data

Shahriar Jarchi, MD

Internal Medicine · Los Angeles, CANPI 1417008772

Payments from drug & device makers

$2,513in general payments, 2019–2025

Across 36 payments — averaging $69.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • Otsuka America Pharmaceutical, Inc.$299
  • Shield Therapeutics Inc$103
  • Johnson & Johnson$74
  • Novo Nordisk$63
  • Lundbeck LLC$62
  • plus $367 from 12 others

What the payments were for

  • Speaking & faculty fees$1,52060%
  • Food & beverage$99340%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,513 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$1,937,533
Medicare patients
1,404
Services billed
22,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,378$500,320
NuplazidPimavanserin Tartrate30$96,795
JardianceEmpagliflozin290$94,103
RexultiBrexpiprazole88$78,444
XareltoRivaroxaban223$78,335
JanuviaSitagliptin Phosphate165$71,276
OzempicSemaglutide63$62,466
Metformin Er GastricMetformin Hcl82$55,184
SantylCollagenase Clostridium Hist.36$50,049
ProcritEpoetin Alfa65$43,414
FarxigaDapagliflozin Propanediol88$39,177
Atorvastatin Calcium2,982$35,215
MyrbetriqMirabegron84$26,638
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate20$24,716
LinzessLinaclotide46$24,545

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt, Retacrit$1,545$533,2481,427 claims
Johnson & JohnsonXarelto, Procrit$74$121,750288 claims
Otsuka America Pharmaceutical, Inc.Rexulti$299$78,44488 claims
Novo NordiskOzempic$63$62,46663 claims
Smith+NephewSantyl$13$50,04936 claims
AbbVieLinzess$59$24,54546 claims
Lilly USA, LLCTrulicity$30$22,73124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →